Hints and tips:
...counterbid for ImClone last year in response to an offer from Bristol-Myers Squibb....
...Bristol Myers Squibb was a rare gainer, its shares lifting 1.7 per cent to $21.02 after the US Food and Drug Administration said analyses of its experimental diabetes drug showed it met the agency’s guidelines...
International Edition